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Abstract
Background—The Fontan operation results in a circulation that is dependent on low pulmonary 
vascular resistance to maintain an adequate cardiac output. Medical therapies that lower 
pulmonary vascular resistance may augment cardiac output and improve long-term outcomes.
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Objectives—This phase I/II clinical trial conducted by the Pediatric Heart Network was 
designed to evaluate short-term safety, pharmacokinetics (PK), and preliminary efficacy of 
udenafil in adolescents following Fontan.
Methods—A 5-day dose-escalation trial was conducted in five study cohorts of six subjects each 
(37.5, 87.5, and 125 mg daily, 37.5 and 87.5 mg by mouth twice daily). A control cohort with 6 
subjects underwent exercise testing only. Adverse events (AEs) were recorded, PK samples were 
collected on study days six through eight, and clinical testing was performed at baseline and day 
five.
Results—The trial enrolled 36 subjects; mean age 15.8 years (58% male). There were no 
significant differences in subject characteristics between cohorts. No drug-related serious AEs 
were reported during the study period; 24 subjects had AEs possibly or probably related to study 
drug. Headache was the most common AE, occurring in 20 of 30 subjects. The 87.5 mg bid cohort 
was well tolerated, achieved the highest maximal concentration (506 ng/mL) and the highest 
average concentration over the dosing interval (279 ng/mL), and was associated with a suggestion 
of improvement in myocardial performance. Exercise performance did not improve in any of the 
dosing cohorts.
Conclusions—Udenafil was well-tolerated at all dosing levels. The 87.5 mg bid cohort achieved 
the highest plasma drug level and was associated with a suggestion of improvement in myocardial 
performance. These data suggest that the 87.5 mg bid regimen may be the most appropriate for a 
Phase III clinical trial.
Keywords
Fontan procedure; pharmacokinetics; heart failure
Introduction
The Fontan operation is a palliative procedure for children born with functional single 
ventricle heart disease1,2. This operation, which creates a total cavopulmonary connection, 
separates the systemic and pulmonary circuits and mitigates pre-existing chronic hypoxemia 
and ventricular volume overload. However, following the Fontan operation there is no 
ventricular pump to propel blood into the pulmonary arteries. Instead, blood returns to the 
lungs via passive flow from the systemic veins. The resulting physiology confers a degree of 
chronic heart failure, characterized by diastolic dysfunction, and a circulation dependent on 
low pulmonary vascular resistance (PVR) in order to maintain an adequate cardiac output 
with a modestly elevated central venous pressure3,4.
Phosphodiesterase Type 5 (PDE5) inhibitors are a unique class of medications that have 
demonstrated utility in reducing PVR and improving ventricular performance in patients 
with pulmonary hypertension and myocardial dysfunction5–10. These characteristics make 
this class of drug an appealing therapy to consider for patients with the Fontan circulation, in 
which the maintenance of low PVR and normal myocardial function are crucial determinants 
of long-term clinical outcomes. Although preliminary studies have demonstrated a modest 
short-term benefit, there are no data regarding the long-term use of this class of medication 
in the Fontan population10–14.
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Udenafil is a novel PDE5 inhibitor that has an established record of safety and efficacy in 
adult males for the indication of erectile dysfunction15–17. In that population, the 
pharmacokinetics (PK) of udenafil (molecular weight 516 g/mole) and the major circulating 
metabolite, DA-8164 (molecular weight 405 g/mole), have been well characterized. Udenafil 
is rapidly absorbed following oral administration, followed by a log-linear decline in plasma 
concentration with a terminal half-life in the range of 16 hours. Both udenafil and DA-8164, 
which is equipotent, are cleared predominantly by hepatic metabolism and then excreted in 
the feces and urine. Udenafil bioavailability is known to increase greater than proportionally 
with increasing dose following single- and multiple-dose administration. Although udenafil 
has been studied in adult males, the safety, PK, and tolerability of udenafil have not been 
evaluated in children or adolescents, in females, or in those who have undergone the Fontan 
operation.
The aims of this study were to: 1) evaluate the short-term safety and tolerability of udenafil 
in male and female adolescents with single ventricle physiology who have undergone the 
Fontan operation, 2) determine the PK of udenafil in this population, and 3) evaluate the 
short-term impact of udenafil on clinical outcome measures affected by this unique form of 
chronic heart failure. The results of this phase I/II clinical trial provide preliminary data to 
aid in dose selection for a phase III clinical trial.
Methods
This multi-center, open-label, dose escalation, safety, PK, and pharmacodynamic study was 
conducted in adolescents with single ventricle physiology after Fontan palliation. Dosing 
cohort size was determined a priori to provide a sample-size sufficient to evaluate short-term 
safety and allow characterization of the PK endpoints in this patient population. The study 
was not powered to detect statistically significant differences in clinical testing. Subjects 
were enrolled in five cohorts of six subjects each at udenafil doses of 37.5 mg, 87.5 mg, and 
125 mg daily, as well as 37.5 mg and 87.5 mg by mouth twice daily (bid) for five days. 
Serum electrolytes and liver enzyme levels were measured, and a pregnancy test was 
obtained and confirmed as negative prior to drug administration. Blood samples for udenafil 
and DA-8164 PK analysis were collected for 48 hours following the last udenafil dose. 
Clinical testing (echocardiography, exercise stress test, and endothelial function assessment) 
was performed at baseline and again on day five. A control cohort of six subjects underwent 
exercise testing without drug administration.
Subjects for this study were recruited from six Pediatric Heart Network (PHN) clinical 
centers in the United States and Canada. Subjects were identified from a review of the 
medical records at each center, and consent with or without assent was obtained as 
appropriate. The study was approved by the Institutional Review Board for the Protection of 
Human Subjects at each of the five sites in the Unites States, and by the Research Ethics 
Board for the site in Canada. Udenafil was used under an Investigational New Drug 
application with the Food and Drug Administration (IND #121,648). A Health Canada No 
Objection Letter was obtained for the use of udenafil in Canada. The study was overseen by 
the PHN’s Data and Safety Monitoring Board, and adverse events were reviewed by the 
PHN’s independent Medical Monitor. Funding for this project was provided by the National 
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Heart, Lung, and Blood Institute and by Mezzion Pharma Co. Ltd. (Seoul, South Korea). 
The authors are solely responsible for the design and conduct of this study, all study 
analyses, the drafting and editing of the paper and its final contents.
Safety / tolerability
Adverse events (AEs) were recorded throughout the eight-day study period and for three 
months thereafter. AEs were classified and reported based on seriousness (serious vs. non-
serious), relation to the study drug (definitely, probably, possibly, or not related), and by 
expectedness (expected vs. unexpected).
PK analysis
On study day six, subjects were admitted to an observation unit where a blood-drawing IV 
was placed. Blood samples for PK analysis were drawn in a non-fasting state at time 0 (just 
prior to final dose) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 hours post-dose. 
Plasma udenafil and DA-8164 concentrations were determined using a validated liquid 
chromatography with tandem mass spectrometry detection (LC/MS-MS) method by 
Nuvisan-GmbH, New Ulm Germany. The lower and upper limits of detection for udenafil 
and DA-8164 were 1.0 ng/mL and 1000 ng/mL. Samples below the limit of quantification 
were to be reported as 0.00 ng/mL for the purpose of calculating descriptive statistics. The 
precision of quality control samples during sample analysis was expressed as the percent 
coefficient of variation (%CV). For plasma udenafil, the mean %CV ranged from 3.3% to 
5.8%. For plasma DA-8146, the mean %CV ranged from 4.7% to 8.7%. Accuracy during 
sample analysis was expressed as percent difference from theoretical (bias). For plasma 
udenafil, the mean bias ranged from −6.6% to 4.8% for calibration standards and −4.3% to 
2.6% for quality control samples. For plasma DA-8146, the mean bias ranged from −1.1% to 
2.2% for calibration standards and −2.4% to −1.1% for quality control samples. PK analysis 
of udenafil and DA-8164 were provided by R. Guttendorf (Aclairo Pharmaceutical 
Development Group, Inc, Vienna, Virginia).
The PK evaluation was based on non-compartmental PK parameters. These parameters 
included maximum plasma concentration (Cmax), time to maximum plasma concentration 
(tmax), area under the plasma concentration versus time curve from time zero through the 
dosing interval (AUC0−τ), average concentration over the dosing interval (Cavg) defined as 
AUC0−τ/τ, the terminal phase rate constant (kel), the terminal half-life (t½) defined as 0.693/
kel, and oral clearance (CL/F). All PK parameters were calculated using WinNonlin 
(Pharsight Corporation, Version 6.4).
Clinical testing—On study day 5 (after eight doses for those randomized to twice daily 
dosing and four doses for those randomized to daily dosing), each subject underwent repeat 
clinical testing. Subjects were instructed to take the scheduled dose of study drug at home 
and arrive such that follow-up testing could start within an hour of the start time of the 
baseline PD tests ensuring that PD parameters were evaluated near peak drug exposure time. 
Subjects were asked to arrive in a fasting, non-caffeinated state, and underwent vascular 
function assessment as their first clinical test. A light snack was provided prior to 
echocardiographic assessment and exercise testing.
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Exercise stress test
Subjects underwent maximal exercise testing using a standard ramp cycle protocol. Expired 
gases were collected and electrocardiographic data were recorded as described previously in 
Fontan protocols published by the Pediatric Heart Network18. The primary outcome of 
interest was maximal oxygen consumption at peak effort. Subjects were judged to achieve a 
maximum exercise performance if the respiratory exchange ratio was ≥ 1.1.
Echocardiography
Echocardiograms were performed by sonographers with specific training for this protocol. 
The primary outcome of interest was the myocardial performance index (MPI) using 
Doppler-based measures of inflow and outflow duration. The duration of inflow into the 
dominant ventricle and outflow across the dominant semilunar valve were measured and 
used to calculate MPI using the standard formula19. Additional tissue Doppler images were 
obtained and used to calculate the tissue Doppler based MPI as previously described20. 
Whenever possible, three measurements were made and the mean duration was used for the 
calculation. All measurements were made by a single reader at the echocardiography core 
lab (The Children’s Hospital of Philadelphia).
Vascular Function
Vascular function was assessed using peripheral arterial tonometry (PAT). Testing was 
performed in a quiet, darkened, temperature-controlled room (maintained at 70° to 75°F), 
and prior to other testing procedures (e.g., stress testing). Subjects were instructed to fast 
and to avoid exposure to caffeine and tobacco for 12 hours prior to testing. The testing 
protocol was performed using the Endo-PAT 2000 device (Itamar Medical, Caesarea, Israel) 
as instructed by the manufacturer and previously reported21,22. Measures of vascular 
function included the natural log transformed reactive hyperemia index (InRHI, the primary 
vascular outcome measure) and augmentation index (AI, a measure of arterial stiffness, the 
secondary outcome measure) normalized to a heart rate of 75 beats per minute. Studies were 
reviewed by the vascular core laboratory (Cincinnati Children’s Hospital Medical Center) 
for purposes of data quality assurance and quality control (QC). A QC score ranging from 1 
(lowest) to 3 (highest) was used to judge the quality of the Endo-PAT measurements. Only 
those studies that had a score of 2 or 3 were used for analysis.
Statistical Methods
Key patient characteristics were compared using ANOVA at baseline among all six cohorts 
to detect potential imbalances. Descriptive statistics (arithmetic mean, standard deviation, 
coefficient of variation, and harmonic mean half-life (0.693/mean ke) values were calculated 
for udenafil and DA-8164 PK parameters. The relationship between udenafil and DA-8164 
Cavg concentration values were inspected for trends likely to be of clinical relevance. The 
relationship between udenafil exposure (Cavg and Cmax values) and age, weight, and gender 
was also examined.
For clinical outcome measures (exercise stress test, echocardiography and vascular 
function), change scores between baseline and follow-up testing were compared using 
ANOVA and visual trend lines. Longitudinal changes within individual cohorts between 
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baseline (day 1) and follow-up (day 5) studies were assessed using a paired t-test. 
Significance was set at p<0.05 for all t-test comparisons. As this was a phase I/II trial and 
not meant to confirm efficacy, p-values were not adjusted for multiple comparisons.
Results
A total of 36 subjects participated in this clinical trial, including 30 subjects who received 
study drug and six additional non-treated subjects that served as controls for the exercise 
stress test. All subjects who provided informed consent successfully completed the trial. 
Subject characteristics are listed in Table 1. The mean subject age was 15.8±1.3 years and 
58% were male. There were no significant differences in key subject characteristics across 
the treatment groups with the exception of ventricular morphology. Overall, slightly more 
than one third of subjects had a dominant right ventricle (36%, n=13). The majority of 
subjects (58%, n=21) did not have a patent fenestration and the baseline mean arterial 
oxygen saturation was 93.8±3.1%.
Udenafil was well tolerated by all subjects at all dosing levels. A single serious unexpected 
AE was reported in this study, which was altered mental status unrelated to the study drug 
with onset nine days after drug discontinuation. This subject was observed in the hospital for 
24 hours and subsequently discharged with no sequelae. No other serious AEs or AEs 
definitely related to the drug were reported. AEs thought to have a possible or probable 
relationship to study drug that occurred in more than one subject were limited to those 
known to be side effects of PDE5 inhibitors (Table 2). In total, 28 subjects (93%) reported at 
least one AE and 24 subjects (80%) experienced AEs determined by the investigators to 
have a possible or probable relationship to study drug. Of these, headache was the most 
common, occurring in 19 (63%) of the 30 subjects. Other AEs possibly or probably related 
to study medication that occurred in more than one subject included: facial flushing (33%), 
spontaneous penile erection (35% of males), nasal congestion (20%), nausea (10%), and 
abdominal discomfort (7%). Reported AEs did not increase with increasing dose.
All 13 scheduled blood samples for the PK analysis of udenafil and DA-8146 were 
successfully collected from each of the 30 subjects in the dosing cohorts at each pre-
specified time point and all serum samples were determined to have a concentration that fell 
within the limits of quantification. Following oral administration of udenafil for five days, 
plasma udenafil concentrations increased rapidly until 1.3 to 2.3 hours followed by a log-
linear decrease over the remainder of the sampling period (Figure 1a). Mean profiles were 
representative of individual subject profiles. Udenafil Cmax and AUC0−τ values increased out 
of proportion to increasing dose following multiple-dose oral administration. After once-
daily dosing, mean udenafil Cmax values increased 4.6-fold and mean AUC0−τ values 
increased 4-fold when dose increased 3.3 times. After twice-daily dosing, mean udenafil 
Cmax values increased 3.3-fold and mean AUC0−τ values increased 3.2-fold when dose 
increased 2.3 times. Oral clearance (CL/F) decreased with increasing dose. Udenafil 
terminal phase half-life was approximately 10 to 13 hours for all 5 dosing regimens (Table 
3). Analysis of PK by gender demonstrated that dose-normalized Cmax and Cavg values were 
not different for the male and female patients with Fontan physiology (Figure 2).
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The PK for DA-8164 was similar to that of udenafil. Plasma concentrations increased 
rapidly over 2 to 4 hours followed by a log-linear decrease over the remainder of the 
sampling period (Figure 1b). Mean profiles were again representative of individual subject 
profiles. After once-daily dosing, mean DA-8164 Cmax values increased 4.2-fold, and mean 
AUC0−τ values increased 4-fold when dose increased 3.3 times. After twice-daily dosing, 
mean DA-8164 Cmax and AUC0−τ values increased approximately proportionally with 
increase in dose; Cmax values increased 1.8-fold and mean AUC0−τ values increased 1.9-fold 
when dose increased 2.3 times. DA-8164 terminal phase half-life was approximately 12 to 
15 hours (Table 4).
Of the 36 subjects who underwent exercise testing, 32 (89%) were able to reach maximal 
effort at both baseline and follow-up exercise testing (Table 5, Figure 3). In the short period 
of study there were no differences in the change in any exercise parameter from baseline to 
follow-up testing across dosing cohorts. Similarly there was no difference from baseline to 
follow-up testing within any individual cohort.
Paired blood pool Doppler data were available for 27 of the 30 subjects, while paired tissue 
Doppler data were available for 26 subjects (Table 6, Figure 4). There were no significant 
differences in change scores across dosing cohorts for either blood pool or tissue Doppler 
based measures. However, there was a significant improvement from baseline to follow-up 
testing in blood pool MPI for those receiving 87.5 mg bid (0.55±0.14 to 0.41±0.08; p=0.04). 
This was not seen with tissue Doppler evaluation.
Paired PAT-derived vascular function data were available in 27 of the 30 subjects (Table 7, 
Figure 5). There was no evidence of significant differences in lnRHI, the primary vascular 
outcome measure, or AI among treatment groups. Similarly, there were no discernible 
differences between paired baseline and follow-up measures of lnRHI or AI in any dosing 
cohort.
Discussion
We report the first phase I/II study of a PDE5 inhibitor in subjects with Fontan physiology. 
In this study we found that udenafil was well-tolerated at all trialed doses, and that the 
dosing regimen of 87.5 mg bid (175 mg/day) provided the highest plasma drug 
concentration and a suggestion of improvement in myocardial performance. Plasma udenafil 
concentration was noted to increase rapidly until Tmax followed by a log-linear decrease in 
concentration over time. While no statistically significant improvements were noted in other 
clinical testing, the duration of the trial was short and the primary purpose of this study was 
to assess safety. These short-term data suggest that udenafil would be suitable for testing in a 
phase III clinical trial, and that the dose of 87.5 mg bid would be the most appropriate.
This study adds to the growing list of studies investigating the potential benefit of 
modulators of PVR for treatment of those with single ventricle (Fontan) circulation-related 
heart failure10–14,23–26. PDE5 inhibitors have been the most frequently studied of the PVR 
modulators, and the results from those studies have been mixed. A number of studies have 
demonstrated acute improvements in exercise performance, ejection fraction, and cardiac 
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output, while the only reported randomized clinical trial showed improvements in some sub-
groups during sub-maximal exercise, but did not detect an improvement in maximal oxygen 
consumption10–14. More recently, investigators have evaluated the effect of Bosentan and 
inhaled prostacyclin on measures of exercise performance23–25. The results of these studies 
were also mixed; one demonstrating a possible benefit and the other demonstrating no 
evidence of benefit. Interestingly, while the improvement noted in the MPI in this study was 
modest, it is in keeping with results from other studies evaluating of PDE5 inhibitors in 
patients with Fontan physiology10,11,26.
The impact of occult liver dysfunction is an important factor when considering drug dosing 
in those who have undergone the Fontan operation. A recent paper evaluated the differences 
between udenafil metabolism in healthy subjects as compared to those with mild or 
moderate liver dysfunction as characterized by Child-Pugh class A and class B 
respectively27. While there was no need for a dose adjustment in those with mild 
impairment, there is suggestion that a 25% dose reduction might be appropriate in those with 
moderate hepatic impairment (class B). However, it should be noted that class B hepatic 
impairment, designated as “moderate” in this study, corresponds to significantly more 
advanced hepatic impairment than that which is typically seen in those with Fontan-
associated liver disease. Further, we excluded potential subjects with known liver cirrhosis 
from this study so the impact of hepatic impairment on our results was likely minimal.
Although the literature regarding modulators of PVR in the Fontan population has continued 
to grow, there has yet to be an adequately powered long-term study of pulmonary 
vasodilators in this cohort. Of the classes of pulmonary vasodilators available, PDE5 
inhibitors have the most acceptable safety profile and are therefore the most appropriate for 
a large-scale clinical trial. Udenafil has an established record of safety in the adult 
population with erectile dysfunction and was very well tolerated in this phase I/II clinical 
trial15,16. In this study 24 of the 30 subjects exposed to study drug reported adverse events 
thought to have a plausible connection to study drug, but these events were well tolerated 
and did not require the cessation of study drug. These results are similar to those reported in 
in a cohort of 40 healthy adult male subjects who were part of a previous safety, tolerability, 
and pharmacokinetic study17. Importantly, no drug-related serious adverse events were 
reported. The PK profile demonstrated in this study is similar to what has been seen in the 
adult population and suggests that twice daily dosing may be most appropriate to achieve the 
highest steady state drug concentration.
While the results of this study are adequate for dose selection for a phase III clinical trial, 
this phase I/II study was, by design, not powered to detect differences in the results of 
clinical testing from baseline to follow-up. Therefore, it is not possible to discern the 
potential clinical benefit of udenafil in the Fontan population from these data. Additionally, 
although the 87.5 mg twice daily dose achieved the highest area under the curve and the 
highest peak plasma concentration, higher doses were purposefully not tested. Dose 
selection was based in part on data from adult populations suggesting that higher doses were 
not well tolerated due to side effects, and therefore would not be practical for use as a daily 
dose for chronic administration.
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Conclusion
This study demonstrates that udenafil was safe and well tolerated at all studied doses in male 
and female adolescents who had undergone Fontan palliation. Following oral administration, 
udenafil was rapidly absorbed with time to maximum concentration ranging from 1.3 to 2.3 
hours. The measured half-life of udenafil was 10 to 13 hours, while that for DA-8164 was 12 
to 15 hours. The dosing cohort that received 87.5 mg bid achieved the highest udenafil and 
DA-8164 plasma levels. With a 5-day treatment period and small sample size, the only 
suggestion of improvement in clinical measures was that noted in the myocardial 
performance index for those in the cohort that received 87.5 mg bid. These data provide 
support for pursuing a phase III trial and suggest that the 87.5 mg bid regimen may be the 
most appropriate dose to study.
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Abbreviations
AE adverse event
AI augmentation index
AUC area under the curve
BID twice daily
Cavg average concentration
Cmax maximal concentration
mg milligrams
mL milliliters
MPI myocardial performance index
ng nanograms
PAT peripheral arterial tonometry
PDE5 phosphodiesterase type 5
PHN Pediatric Heart Network
PK pharmacokinetic
PVR pulmonary vascular resistance
QC quality control
RHI reactive hyperemia index
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Highlights
• Udenafil is a novel PDE-5 inhibitor with pharmacokinetics suggesting twice 
daily dosing.
• There were no drug-related serious adverse events in a cohort of adolescent’s 
who had undergone the Fontan operation and were exposed to a five-day 
course of udenafil.
• A dose of 87.5 mg twice daily achieved the highest maximal and average 
serum concentration and was associated with a suggestion of improvement in 
myocardial performance.
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Figure 1. 
Mean concentration-time profile for udenafil (a) and DA-8164 (b) following oral 
administration of 37.5, 87.5, and 125 mg daily, and 37.5 and 87.5 mg twice daily. For twice 
daily dosing, the second twelve hours is imputed from the first twelve hours.
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Figure 2. 
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Individual subject and mean (95% confidence interval) dose-normalized udenafil Cmax (a) 
and Cavg (b) values following oral administration of udenafil for 5 days to male (N=17) and 
female (N=13).
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Figure 3. 
Change in maximal oxygen consumption (mL/kg/min) baseline to day five by treatment 
group. A positive change indicates improvement. Individual subject values are represented 
by the “o” on the figure.
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Figure 4. 
Change in blood pool Myocardial Performance Index baseline to day five by treatment 
group. A negative change indicates improvement. Individual subject values are represented 
by the “o” on the figure.
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Figure 5. 
Change in the natural log of Reactive Hyperemia Index baseline to day five by treatment 
group. A positive change indicates an improvement. Individual subject values are 
represented by the “o” on the figure.
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